AVITA Medical, Inc. Stock

Equities

RCEL

US05380C1027

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
8.52 USD +2.65% Intraday chart for AVITA Medical, Inc. -1.39% -37.90%
Sales 2024 * 115M 75.33M Sales 2025 * 164M 107M Capitalization 337M 220M
Net income 2024 * -56M -36.58M Net income 2025 * -17M -11.1M EV / Sales 2024 * 2.75 x
Net cash position 2024 * 19.8M 12.93M Net cash position 2025 * 1.85M 1.21M EV / Sales 2025 * 2.05 x
P/E ratio 2024 *
-6.23 x
P/E ratio 2025 *
-31.5 x
Employees 207
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.34%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on AVITA Medical, Inc.

1 day+2.65%
1 week-1.39%
Current month-46.85%
1 month-46.72%
3 months-48.77%
6 months-9.75%
Current year-37.90%
More quotes
1 week
8.01
Extreme 8.01
9.27
1 month
8.01
Extreme 8.01
16.65
Current year
8.01
Extreme 8.01
18.93
1 year
8.01
Extreme 8.01
21.70
3 years
4.41
Extreme 4.4102
22.49
5 years
4.41
Extreme 4.4102
55.35
10 years
3.75
Extreme 3.75
55.35
More quotes
Date Price Change Volume
24-04-26 8.52 +2.65% 285,980
24-04-25 8.3 -3.15% 251,806
24-04-24 8.57 -4.57% 149,342
24-04-23 8.98 +5.03% 201,977
24-04-22 8.55 -1.04% 555,118

Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm EDT

More quotes
AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
13.06 AUD
Average target price
39.74 AUD
Spread / Average Target
+204.17%
Consensus